Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response

Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response

Prediction of therapeutic outcomes is important for cancer patients in order to reduce side effects and improve the efficacy of anti-cancer drugs. Currently, the most widely accepted method for predicting the efficacy of anti-cancer drugs is gene panel testing based on next-generation sequencing. Ho...

Full description

Bibliographic Details
Main Authors: Yoshiyuki Tsukamoto, Yuka Hirashita, Tomotaka Shibata, Shoichi Fumoto, Shusaku Kurogi, Chisato Nakada, Keisuke Kinoshita, Takafumi Fuchino, Kazunari Murakami, Masafumi Inomata, Masatsugu Moriyama, Naoki Hijiya
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Cancers
Subjects:
functional testing
patient derived cancer organoids (PDCOs)
patient derived explants (PDEs)
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
lactate dehydrogenase (LDH)
spheroid
Online Access:https://www.mdpi.com/2072-6694/15/16/4104

Internet

https://www.mdpi.com/2072-6694/15/16/4104

Similar Items